Novo Nordisk Presents New Data at ObesityWeek 2026
Novo Nordisk shared new clinical data at ObesityWeek 2026 regarding the impact of its investigational amylin-based therapies on bone health and pediatric BMI.
Stocks · News reference
Novo Nordisk unveils Phase 3 CagriSema weight-loss data and real-world Wegovy food-noise reductions at ObesityWeek 2026 in Washington, D.C.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Novo Nordisk shared new clinical data at ObesityWeek 2026 regarding the impact of its investigational amylin-based therapies on bone health and pediatric BMI.
The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.
Novo Nordisk has partnered with AI-technology company nference to advance research into cardiometabolic diseases, including obesity, diabetes, and cardiovascular conditions.
The professional cycling team composed of riders living with type 1 diabetes will be rebranded as Team Novo starting in 2027, with Novo Nordisk continuing as the title sponsor.
Novo Nordisk has introduced a reimagined Novocare® membership experience to provide enhanced support, resources, and digital tools for patients using Wegovy®.
Johnson & Johnson demonstrates strong revenue growth with consistent quarter-over-quarter increases, while Novo Nordisk struggles with largely flat revenue despite a notable spike in Q1 2026. JNJ's diverse portfolio of 28+ billion-dollar products contrasts with Novo Nordisk's challenges as competitors catch up in the GLP-1 weight loss market.